Clinical Trial

A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multicenter, open-label, phase II study of YL201 in China to evaluate the efficacy, safety, and PK characteristics of YL201 on mCRPC.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2024-01-28; most recent amendment 2025-08-25.
Status change: Not Yet Recruiting → Recruiting 2024-03-12
Trial Details
NCT Number NCT06241846
Lead Sponsor MediLink Therapeutics (Suzhou) Co., Ltd.
Conditions Metastatic Castration-resistant Prostate Cancer (mCRPC)
Enrollment 100 participants
Start Date 2024-02-22
Primary Completion 2027-02 (estimated)
Study Completion 2029-02 (estimated)
Updated on ClinicalTrials.gov 2025-08-27